Clinical trials: Peripheral T Cells Lymphoma (PTCL), active
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
This is a phase I/II clinical trial to evaluate the efficacy and safety of Golidocitinib combined with Pomalidomide for relapsed/refractory peripheral T-cell lymphoma.
- Trial name
- NCT06855823
- Testing
- Golicitinib combined with Pomadomide
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sun Yat-sen University
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma
- Conditions
- Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- CERTAIN (NCT04526834)
- Testing
- CD30.CAR-T
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tessa Therapeutics
Peripheral T-cell Lymphoma
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).
- Trial name
- NCT07234162
- Testing
- Golidocitinib, Chidamide, Gemcitabine
- Where
- 51 sites in China, Taiwan and 1 more
- Volunteers
- 218 people
- Sponsor
- Dizal Pharmaceuticals
PTCL, Refractory
Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL
To evaluate the safety and efficacy of Zeprumetostat-based combination therapy, selected according to genotyping results, in patients with primary refractory peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT07493330
- Testing
- Zeprumetostat+Azacitadine, Zeprumetostat+Decitabine, Zeprumetostat+Chidamide
- Volunteers
- 86 people
- Sponsor
- Ruijin Hospital
Peripheral T Cell Lymphoma
A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).
- Trial name
- NCT07180771
- Testing
- BR101801
- Volunteers
- 44 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral…
- Conditions
- Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
- Trial name
- NCT06561048
- Testing
- Soquelitinib, Belinostat, Pralatrexate
- Where
- 37 sites in United States, Australia and 1 more
- Volunteers
- 150 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Newly Diagnosed Peripheral T-cell Lymphoma
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
This is a prospective, single arm, single center study to evaluate the efficacy and safety of Duvelisib combined with Chidamide in the treatment of newly diagnosed peripheral T-cell lymphoma.
- Trial name
- NCT05976997
- Testing
- Duvelisib, Chidamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Liling Zhang
Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. These T-cell neoplasms account for approximately 10-15% of all lymphomas.
- Conditions
- Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
- Trial name
- NCT07535762
- Testing
- Aclarubicin, Cyclophosphamide, Vincristine
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
T-cell NHL (PTCL or CTCL)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
- Trial name
- NCT07192471
- Testing
- KK2223
- Where
- 22 sites in United States, Italy and 1 more
- Volunteers
- 72 people
- Sponsor
- Kyowa Kirin, Inc.
PTCL, CTCL
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D)…
- Trial name
- NCT03240211
- Testing
- Pembrolizumab, Pralatrexate, Decitabine
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Virginia
Peripheral T Cell Lymphoma
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
This is a randomized, open-label, active controlled, multi-center, phase 3 clinical study to compare the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with Chidamide in patients with relapsed/refractory…
- Trial name
- NCT04668690
- Testing
- Mitoxantrone Hydrochloride Liposome Injection, Chidamide
- Where
- China
- Volunteers
- 193 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Peripheral T Cell Lymphoma, Relapse/Recurrence
Study of Lacutamab in Peripheral T-cell Lymphoma
This is an open-label multicenter randomized non comparative phase II study to evaluate the safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with Refractory/Relapsing (R/R) KIR3DL2 positive…
- Trial name
- NCT04984837
- Testing
- Lacutamab, Gemcitabine, Oxaliplatine
- Where
- 64 sites in Belgium, France and 2 more
- Volunteers
- 49 people
- Sponsor
- The Lymphoma Academic Research Organisation
T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This is an open-label, phase I/II study of duvelisib in combination with Venetoclax for patients with relapsed/refractory NHL. Duvelisib is an FDA approved, marketed product used to treat certain patients with leukemia and…
- Trial name
- NCT06810778
- Testing
- Duvelisib, Venetoclax
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.
- Conditions
- Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma
- Trial name
- NCT06151106
- Testing
- Chidamide combined with Duvillisib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Relapsed or Refractory Peripheral T-cell Lymphoma
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
- Trial name
- NCT05833724
- Testing
- Chidamide
- Where
- 6 sites in Taiwan
- Volunteers
- 33 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
Peripheral T-cell Lymphoma
Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma
This is a Phase I/II, open-label, single-arm study investigating the combination of chidamide and golidocitinib in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT06757387
- Testing
- chidamide and golidocitinib
- Volunteers
- 45 people
- Sponsor
- Peking University Cancer Hospital & Institute
Newly Diagnosed Peripheral T-cell Lymphoma
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
The goal of this clinical trial is to compare Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL. The main question it aims to answer are: •Whether Chi-BEAM improves patient survival compared to BEAM group…
- Trial name
- NCT05931263
- Testing
- C-BEAM Regimen, BEAM Regimen
- Where
- China
- Volunteers
- 104 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Maintenance Treatment of Peripheral T-cell Lymphoma
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
This is a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating golidocitinib as maintenance therapy in adult patients with peripheral T-cell lymphoma (PTCL) who achieved complete response (CR) or…
- Trial name
- T-START-M1 (NCT07300514)
- Testing
- PET-CTandct- DNAdetection, golidocitinib
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Fudan University
Peripheral T Cells Lymphoma (PTCL), Follicular Helper T-Cell Lymphoma
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
This study is a platform trial for the evaluation of new drugs or combination of drugs in relapsed or refractory peripheral T-cell lymphomas.
- Trial name
- PlaTform (NCT07018752)
- Testing
- roginolisib, golcadomide, azacitidine
- Where
- 20 sites in France
- Volunteers
- 80 people
- Sponsor
- The Lymphoma Academic Research Organisation
Peripheral T Cells Lymphoma (PTCL)
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of linperlisib combined with chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma
- Trial name
- NCT07139353
- Testing
- Linperlisib, Chidamide
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University